Replikins announced influenza H5N1 vaccine ready for testing

Replikins, Ltd., announced on Wednesday that it has successfully developed a vaccine against the influenza strain H5N1 that is now ready for testing.

Replikins also released an analysis of the genomic structures of five strains of influenza, including H3N2, H2N2, H1N1, H7N9 and H5N1. The genetic structures are replikins, a specific type of structure which relates directly to the quick duplication and outbreak of viruses.

Replikins has a track record of successfully predicting potential viruses, including the prediction of the H1N1 pandemic of 2009 and the outbreak of H5N1 in Indonesia between 2006 and 2008. The company is currently preparing vaccine candidates against the influenza strains H7N9 and H5N1; it is expecting to release these candidate vaccines at the World Vaccine Congress Europe in Lille, France, in October.

Replikins has a proprietary software that targets specific aspects of the virus. The company bases its vaccines on premature "scout" data, which allows for its vaccines to be produced at least seven months earlier than the competition. This technique also allows for prompt development of a vaccine to counter an emerging outbreak.

Replikins used the "scout" technique to successfully manufacture and test a vaccine against the H5N1 avian bird flu in chickens in 2009. The vaccine was manufactured in 7 days, shipped in freeze-dried form and administered through the respiratory passage. By immunizing the chickens, the virus was prevented from spreading or mutating into a stronger strain.